China Large Volume Parenteral (LVP) Industry Report, 2013-2015
Under the context of China's medical reform and sustainable development of the pharmaceutical market, the output and demand of Large Volume Parenteral (LVP) which is one of the top five Chinese preparations have grown year by year. In 2006-2012, China’s injection output presented the CAGR of 19.2%. However, due to the low barriers to entry, China has seen some signs of the surplus injection capacity, which exceeds the demand by roughly 40%.
Overcapacity and fierce competition are caused by the irrational injection product structure and homogeneity. For example, the output and sales volume of fluid balance injection products with low added value account for 89% of the injection market, but the sales revenue only shares 47%. At the same time, the market demand for amino acids, fat emulsion dual-chamber bags, fat emulsion, total parenteral nutrition, hydroxyethyl starch and unique traditional Chinese medicine injection is quite strong.
Compared to Europe and other developed countries, the concentration degree of Chinese LVP market is still lower. At present, 200 ones of 400 qualified Chinese LVP enterprises run business soundly. By output, the top 10 Chinese companies contribute about 65%; in terms of sales revenue, they devote about 40 %.
Like other chemical preparation segments, Chinese high-end LVP market is still dominated by foreign pharmaceutical companies such as Japan Otsuka, Germany Fresenius Kabi, and USA Baxter.
Take fat emulsion products for example. Fat emulsion is imported by China frequently as a blood and hematopoietic system drug in recent years, with its import volume having been at the high level of typical urban hospitals in 22 Chinese cities for consecutive years. Particularly, the procurement value of moderate and long-chain fat emulsion imported by Chinese typical hospitals hit RMB354million. In China, fat emulsion injection suppliers include Kelun Pharma, Sino-Swed Pharmaceutical Corp, Ltd. (under Fresenius Kabi) and Guangzhou Baxter Qiaoguang (under Baxter) with the respective output of 14.19 million bottles/bags, 8.1 million bottles / bags (including medium/long-chain fat emulsion) and 5.69 million bottles/bags (medium/long-chain fat emulsion) in 2012.
The report highlights the followings:
Overcapacity and fierce competition are caused by the irrational injection product structure and homogeneity. For example, the output and sales volume of fluid balance injection products with low added value account for 89% of the injection market, but the sales revenue only shares 47%. At the same time, the market demand for amino acids, fat emulsion dual-chamber bags, fat emulsion, total parenteral nutrition, hydroxyethyl starch and unique traditional Chinese medicine injection is quite strong.
Compared to Europe and other developed countries, the concentration degree of Chinese LVP market is still lower. At present, 200 ones of 400 qualified Chinese LVP enterprises run business soundly. By output, the top 10 Chinese companies contribute about 65%; in terms of sales revenue, they devote about 40 %.
Like other chemical preparation segments, Chinese high-end LVP market is still dominated by foreign pharmaceutical companies such as Japan Otsuka, Germany Fresenius Kabi, and USA Baxter.
Take fat emulsion products for example. Fat emulsion is imported by China frequently as a blood and hematopoietic system drug in recent years, with its import volume having been at the high level of typical urban hospitals in 22 Chinese cities for consecutive years. Particularly, the procurement value of moderate and long-chain fat emulsion imported by Chinese typical hospitals hit RMB354million. In China, fat emulsion injection suppliers include Kelun Pharma, Sino-Swed Pharmaceutical Corp, Ltd. (under Fresenius Kabi) and Guangzhou Baxter Qiaoguang (under Baxter) with the respective output of 14.19 million bottles/bags, 8.1 million bottles / bags (including medium/long-chain fat emulsion) and 5.69 million bottles/bags (medium/long-chain fat emulsion) in 2012.
The report highlights the followings:
- Status quo, competition patterns, product structure, regional distribution and development forecast of Chinese LVP market;
- Status quo and competition patterns of fluid balance injection, therapeutic injection, nutrition injection, injection for blood volume expansion and peritoneal dialysis fluid injection and other market segments;
- Operation, LVP business and prospects of 10 companies including Kelun Pharma, China Resources Double-Crane, Fengyuan Pharmaceutical, Huaren Pharmaceutical, Southwest Pharmaceutical and Lijun International Pharmaceutical.
1 OVERVIEW OF LVP
1.1 Definition and Classification
1.2 Industry Chain
2 OVERVIEW OF CHINA LVP INDUSTRY DEVELOPMENT
2.1 Status Quo
2.2 Competition Pattern
2.3 Product Structure
2.4 Regional Distribution
2. 5 DEVELOPMENT FORECAST
3 CHINESE LVP MARKET SEGMENTS
3.1 Injection for Fluid Balance
3.2 Therapeutic Injection
3.3 Nutritious Injection
3.3.1 Fructose Injection
3.3.2 Amino Acid Injection
3.3.3 Fat Emulsion Injection
3.4 Injection for Blood Volume Expansion
3.4.1 Dextran Injection
3.4.2 Hydroxyethyl Starch Injection
3.5 Peritoneal Dialysis Solution
4 MAIN COMPANIES
4.1 Kelun Pharma
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 Clients and Suppliers
4.1.6 R & D and Investment
4.1.7 LVP Business
4.1.8 Development Forecast
4.2 China Resources Double-Crane
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 Major Clients
4.2.6 LVP Business
4.2.7 Development Forecast
4.3 Fengyuan Pharmaceutical
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 Clients and Suppliers
4.3.6 LVP Business
4.3.7 Development Forecast
4.4 Huaren Pharmaceutical
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 Clients and Suppliers
4.4.6 R & D and Investment
4.4.7 Development Forecast
4.5 Southwest Pharmaceutical
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 Major Clients
4.5.6 LVP Business
4.5.7 Development Forecast
4.6 Lijun International Pharmaceutical (Holding)
4.6.1 Profile
4.6.2 Operation
4.6.3 Shijiazhuang No.4 Pharmaceutical
4.7 Other Companies
4.7.1 Qingzhou Yaowang Medicine
4.7.2 Jilin Dubang Pharmaceutical
4.7.3 Shandong Lukang Cisen Pharmaceutical
4.7.4 China Otsuka Pharmaceutical
5 CHINA LVP INDUSTRY SUMMARY AND DEVELOPMENT PREDICTION
5.1 Market Size to Ascend but Capacity Growth to Slow Down
5.2 Industry Concentration to Improve and Large Players with obvious Competitive Edges
5.3 Product Structure to Upgrade and New LVP products Development to be Trend
1.1 Definition and Classification
1.2 Industry Chain
2 OVERVIEW OF CHINA LVP INDUSTRY DEVELOPMENT
2.1 Status Quo
2.2 Competition Pattern
2.3 Product Structure
2.4 Regional Distribution
2. 5 DEVELOPMENT FORECAST
3 CHINESE LVP MARKET SEGMENTS
3.1 Injection for Fluid Balance
3.2 Therapeutic Injection
3.3 Nutritious Injection
3.3.1 Fructose Injection
3.3.2 Amino Acid Injection
3.3.3 Fat Emulsion Injection
3.4 Injection for Blood Volume Expansion
3.4.1 Dextran Injection
3.4.2 Hydroxyethyl Starch Injection
3.5 Peritoneal Dialysis Solution
4 MAIN COMPANIES
4.1 Kelun Pharma
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 Clients and Suppliers
4.1.6 R & D and Investment
4.1.7 LVP Business
4.1.8 Development Forecast
4.2 China Resources Double-Crane
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 Major Clients
4.2.6 LVP Business
4.2.7 Development Forecast
4.3 Fengyuan Pharmaceutical
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 Clients and Suppliers
4.3.6 LVP Business
4.3.7 Development Forecast
4.4 Huaren Pharmaceutical
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 Clients and Suppliers
4.4.6 R & D and Investment
4.4.7 Development Forecast
4.5 Southwest Pharmaceutical
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 Major Clients
4.5.6 LVP Business
4.5.7 Development Forecast
4.6 Lijun International Pharmaceutical (Holding)
4.6.1 Profile
4.6.2 Operation
4.6.3 Shijiazhuang No.4 Pharmaceutical
4.7 Other Companies
4.7.1 Qingzhou Yaowang Medicine
4.7.2 Jilin Dubang Pharmaceutical
4.7.3 Shandong Lukang Cisen Pharmaceutical
4.7.4 China Otsuka Pharmaceutical
5 CHINA LVP INDUSTRY SUMMARY AND DEVELOPMENT PREDICTION
5.1 Market Size to Ascend but Capacity Growth to Slow Down
5.2 Industry Concentration to Improve and Large Players with obvious Competitive Edges
5.3 Product Structure to Upgrade and New LVP products Development to be Trend
SELECTED CHARTS
Classification, Application and Commodities of LVP (by Clinical Use)
LVP Industry Chain
LVP Output and YoY Growth Rate in China, 2008-2012
Competition Patterns of Chinese LVP Companies (by Output), 2012
Competition Patterns of Chinese LVP Companies (by Sales Volume or Value), 2011
Top 10 LVP Varieties and Output in China, 2011-2012
Proportion of LVP Sales Volume or Value (by Product) in China, 2011
Sales Volume / Value Growth Rate of Major LVP Varieties in China, 2007-2011
Regional Distribution of LVP (by Output) in China, 2011-2012
Major Varieties and Output of Fluid Balance Injection in China, 2010-2012
Major Varieties and Output of Therapeutic Injection in China, 2010-2012
Major Mannitol Injection Enterprises and Their Output in China, 2012
Bid Prices of Some National Essential Drugs in China, 2013
Major Fructose (10%, 500ml) Injection Enterprises and Their Output in China, 2011-2012
Major Glycerol and Fructose Sodium Chloride Injection (CO 250ml) Enterprises and Their Output in China, 2011-2012
Amino Acid Injection Varieties and Major Enterprises and Their Output in China, 2012
Major N (2)-L-propylamine acyl-L-glutamyl Injection Enterprises and Their Output in China, 2012
Purchase Costs of Imported N (2)-L-propylamine acyl-L-glutamyl of Typical Hospitals in 22 Chinese Cities, 2010-2012
Major Fat Emulsion Injection Enterprises and Their Output in China, 2012
Purchase Costs of Imported Fat Emulsion Injection of Typical Hospitals in 22 Chinese Cities, 2010-2012
Major Dextran Injection Enterprises and Their Output in China, 2012
Major Hydroxyethyl Starch Injection Enterprises and Their Output in China, 2012
Purchase Costs of Imported Hydroxyethyl Starch of Typical Hospitals in 22 Chinese Cities, 2010-2012
Purchase Costs of Peritoneal Dialysis Solution of Typical Hospitals in 22 Chinese Cities, 2010-2012
Major Peritoneal Dialysis Solution Enterprises and Their Output in China, 2012
Revenue and Profit of Kelun Pharma, 2008-2013
Revenue of Kelun Pharma (by Product) , 2008-2013
Revenue of Kelun (by Region), 2008-2013
Gross Margin of Kelun Pharma (by Product), 2008-2013
Kelun Pharma’s Revenue from Top 5 Clients and % of Total Revenue, 2008-2013
Kelun Pharma’s Procurement from Top 5 Suppliers and % of Total Procurement, 2008-2012
R & D Costs and % of Total Revenue of Kelun Pharma, 2011-2013
LVP Output, Sales Volume and Inventory of Kelun Pharma, 2011-2012
LVP Revenue and Gross Margin of Kelun Pharma, 2008-2013
LVP Revenue of Kelun (by Product), 2008-2013
Revenue and Net Income of Kelun Pharma, 2012-2015E
Revenue and Profit of China Resources Double-Crane, 2008-2013
Revenue of China Resources Double-Crane (by Product), 2008-2013
Revenue of China Resources Double-Crane (by Region), 2008-2013
Revenue of China Resources Double-Crane (by Product), 2008-2013
China Resources Double-Crane’s Revenue from Top 5 Clients and % of Total Revenue, 2008-2013
Name List and Revenue Contribution of Top 5 Clients of China Resources Double-Crane, H1 2013
Injection Output of China Resources Double-Crane, 2010-2012
Injection Revenue and Gross Margin of China Resources Double-Crane, 2008-2013
Progress of Online Projects of China Resources Double-Crane, by Jun 2013
Revenue and Net Income of China Resources Double-Crane, 2012-2015E
Revenue and Net Income of Fengyuan Pharmaceutical, 2008-2013
Revenue of Fengyuan Pharmaceutical (by Product), 2008-2013
Revenue of Fengyuan Pharmaceutical (by Region), 2008-2013
Gross Margin of Fengyuan Pharmaceutical (by Product), 2008-2013
Fengyuan Pharmaceutical’s Revenue from Top 5 Clients and % of Total Revenue, 2008-2013
Name List and Revenue Contribution of Top 5 Clients of Fengyuan Pharmaceutical, 2012-H1 2013
Fengyuan Pharmaceutical’s Procurement from Top 5 Suppliers and % of Total Procurement, 2008-2013
Name List and Procurement of Top 5 Suppliers of Fengyuan Pharmaceutical, 2012
LVP Output of Fengyuan Pharmaceutical, 2010-2012
Revenue and Net Income of Fengyuan Pharmaceutical , 2012-2015E
LVP Output, Sales Volume and Inventory of Huaren Pharmaceutical, 2011-2012
Revenue and Net Income of Huaren Pharmaceutical, 2008-2013
Revenue of Huaren Pharmaceutical (by Product), 2008-2013
Revenue of Huaren Pharmaceutical (by Region), 2008-2013
Revenue of Huaren Pharmaceutical (by Product), 2008-2013
Huaren Pharmaceutical’s Revenue from Top 5 Clients and % of Total Revenue, 2008-2013
Name List and Procurement of Top 5 Suppliers of Huaren Pharmaceutical, H1 2013
Huaren Pharmaceutical’s Procurement from Top 5 Suppliers and % of Total Procurement, 2008-2013
Name List and Revenue Contribution of Top 5 Clients of Huaren Pharmaceutical, H1 2013
R & D Costs and % of Total Revenue of Huaren Pharmaceutical, 2008-2013
Progress of Major R & D Projects of Huaren Pharmaceutical, by 2013
Revenue and Net Income of Huaren Pharmaceutical , 2012-2015E
Revenue and Net Income of Southwest Pharmaceutical, 2008-2013
Operating Revenue of Southwest Pharmaceutical (by Product), 2008-2013
Revenue of Southwest Pharmaceutical (by Region), 2008-2013
Gross Margin of Southwest Pharmaceutical (by Product), 2008-2013
Southwest Pharmaceutical’s Revenue from Top 5 Clients and % of Total Revenue, 2008-2012
Name List and Revenue Contribution of Top 5 Clients of Southwest Pharmaceutical, 2012
LVP Revenue and Gross Margin of Southwest Pharmaceutical , 2008-2013
Injection Output of Southwest Pharmaceutical, 2010-2012
Revenue and Net Income of Southwest Pharmaceutical, 2012-2015E
Revenue of Lijun International Pharmaceutical (Holding), 2011-2013
Revenue of Shijiazhuang No.4 Pharmaceutical (by Product), 2011-2013
Gross Margin of Shijiazhuang No.4 Pharmaceutical , 2008-2013
Revenue and Net Income of Jin Jian Pharmaceutical, 2008-2013
LVP Output of Jin Jian Pharmaceutical, 2010-2012
Revenue and Gross Margin of Jin Jian Pharmaceutical, 2008-2013
Injection Output of Qingzhou Yaowang Medicine, 2010-2012
Injection Products and Prices of Qingzhou Yaowang Medicine
LVP Output of Dubang Pharmaceutical, 2010-2012
LVP Output of Shandong Lukang Cisen Pharmaceutical, 2010-2012
LVP Output of China Otsuka Pharmaceutical, 2010-2012
Major Injection Products of China Otsuka Pharmaceutical
Injection Output and Demand in China, 2012-2015E
Output of Top 10 Injection Producers in China, 2011-2012
LVP Revenue of Major Chinese Producers, 2008-2012
LVP Gross Margin of Major Chinese Producers, 2008-2013
Proportion of LVP Sales Volume or Value (by Product) in China, 2015E
Classification, Application and Commodities of LVP (by Clinical Use)
LVP Industry Chain
LVP Output and YoY Growth Rate in China, 2008-2012
Competition Patterns of Chinese LVP Companies (by Output), 2012
Competition Patterns of Chinese LVP Companies (by Sales Volume or Value), 2011
Top 10 LVP Varieties and Output in China, 2011-2012
Proportion of LVP Sales Volume or Value (by Product) in China, 2011
Sales Volume / Value Growth Rate of Major LVP Varieties in China, 2007-2011
Regional Distribution of LVP (by Output) in China, 2011-2012
Major Varieties and Output of Fluid Balance Injection in China, 2010-2012
Major Varieties and Output of Therapeutic Injection in China, 2010-2012
Major Mannitol Injection Enterprises and Their Output in China, 2012
Bid Prices of Some National Essential Drugs in China, 2013
Major Fructose (10%, 500ml) Injection Enterprises and Their Output in China, 2011-2012
Major Glycerol and Fructose Sodium Chloride Injection (CO 250ml) Enterprises and Their Output in China, 2011-2012
Amino Acid Injection Varieties and Major Enterprises and Their Output in China, 2012
Major N (2)-L-propylamine acyl-L-glutamyl Injection Enterprises and Their Output in China, 2012
Purchase Costs of Imported N (2)-L-propylamine acyl-L-glutamyl of Typical Hospitals in 22 Chinese Cities, 2010-2012
Major Fat Emulsion Injection Enterprises and Their Output in China, 2012
Purchase Costs of Imported Fat Emulsion Injection of Typical Hospitals in 22 Chinese Cities, 2010-2012
Major Dextran Injection Enterprises and Their Output in China, 2012
Major Hydroxyethyl Starch Injection Enterprises and Their Output in China, 2012
Purchase Costs of Imported Hydroxyethyl Starch of Typical Hospitals in 22 Chinese Cities, 2010-2012
Purchase Costs of Peritoneal Dialysis Solution of Typical Hospitals in 22 Chinese Cities, 2010-2012
Major Peritoneal Dialysis Solution Enterprises and Their Output in China, 2012
Revenue and Profit of Kelun Pharma, 2008-2013
Revenue of Kelun Pharma (by Product) , 2008-2013
Revenue of Kelun (by Region), 2008-2013
Gross Margin of Kelun Pharma (by Product), 2008-2013
Kelun Pharma’s Revenue from Top 5 Clients and % of Total Revenue, 2008-2013
Kelun Pharma’s Procurement from Top 5 Suppliers and % of Total Procurement, 2008-2012
R & D Costs and % of Total Revenue of Kelun Pharma, 2011-2013
LVP Output, Sales Volume and Inventory of Kelun Pharma, 2011-2012
LVP Revenue and Gross Margin of Kelun Pharma, 2008-2013
LVP Revenue of Kelun (by Product), 2008-2013
Revenue and Net Income of Kelun Pharma, 2012-2015E
Revenue and Profit of China Resources Double-Crane, 2008-2013
Revenue of China Resources Double-Crane (by Product), 2008-2013
Revenue of China Resources Double-Crane (by Region), 2008-2013
Revenue of China Resources Double-Crane (by Product), 2008-2013
China Resources Double-Crane’s Revenue from Top 5 Clients and % of Total Revenue, 2008-2013
Name List and Revenue Contribution of Top 5 Clients of China Resources Double-Crane, H1 2013
Injection Output of China Resources Double-Crane, 2010-2012
Injection Revenue and Gross Margin of China Resources Double-Crane, 2008-2013
Progress of Online Projects of China Resources Double-Crane, by Jun 2013
Revenue and Net Income of China Resources Double-Crane, 2012-2015E
Revenue and Net Income of Fengyuan Pharmaceutical, 2008-2013
Revenue of Fengyuan Pharmaceutical (by Product), 2008-2013
Revenue of Fengyuan Pharmaceutical (by Region), 2008-2013
Gross Margin of Fengyuan Pharmaceutical (by Product), 2008-2013
Fengyuan Pharmaceutical’s Revenue from Top 5 Clients and % of Total Revenue, 2008-2013
Name List and Revenue Contribution of Top 5 Clients of Fengyuan Pharmaceutical, 2012-H1 2013
Fengyuan Pharmaceutical’s Procurement from Top 5 Suppliers and % of Total Procurement, 2008-2013
Name List and Procurement of Top 5 Suppliers of Fengyuan Pharmaceutical, 2012
LVP Output of Fengyuan Pharmaceutical, 2010-2012
Revenue and Net Income of Fengyuan Pharmaceutical , 2012-2015E
LVP Output, Sales Volume and Inventory of Huaren Pharmaceutical, 2011-2012
Revenue and Net Income of Huaren Pharmaceutical, 2008-2013
Revenue of Huaren Pharmaceutical (by Product), 2008-2013
Revenue of Huaren Pharmaceutical (by Region), 2008-2013
Revenue of Huaren Pharmaceutical (by Product), 2008-2013
Huaren Pharmaceutical’s Revenue from Top 5 Clients and % of Total Revenue, 2008-2013
Name List and Procurement of Top 5 Suppliers of Huaren Pharmaceutical, H1 2013
Huaren Pharmaceutical’s Procurement from Top 5 Suppliers and % of Total Procurement, 2008-2013
Name List and Revenue Contribution of Top 5 Clients of Huaren Pharmaceutical, H1 2013
R & D Costs and % of Total Revenue of Huaren Pharmaceutical, 2008-2013
Progress of Major R & D Projects of Huaren Pharmaceutical, by 2013
Revenue and Net Income of Huaren Pharmaceutical , 2012-2015E
Revenue and Net Income of Southwest Pharmaceutical, 2008-2013
Operating Revenue of Southwest Pharmaceutical (by Product), 2008-2013
Revenue of Southwest Pharmaceutical (by Region), 2008-2013
Gross Margin of Southwest Pharmaceutical (by Product), 2008-2013
Southwest Pharmaceutical’s Revenue from Top 5 Clients and % of Total Revenue, 2008-2012
Name List and Revenue Contribution of Top 5 Clients of Southwest Pharmaceutical, 2012
LVP Revenue and Gross Margin of Southwest Pharmaceutical , 2008-2013
Injection Output of Southwest Pharmaceutical, 2010-2012
Revenue and Net Income of Southwest Pharmaceutical, 2012-2015E
Revenue of Lijun International Pharmaceutical (Holding), 2011-2013
Revenue of Shijiazhuang No.4 Pharmaceutical (by Product), 2011-2013
Gross Margin of Shijiazhuang No.4 Pharmaceutical , 2008-2013
Revenue and Net Income of Jin Jian Pharmaceutical, 2008-2013
LVP Output of Jin Jian Pharmaceutical, 2010-2012
Revenue and Gross Margin of Jin Jian Pharmaceutical, 2008-2013
Injection Output of Qingzhou Yaowang Medicine, 2010-2012
Injection Products and Prices of Qingzhou Yaowang Medicine
LVP Output of Dubang Pharmaceutical, 2010-2012
LVP Output of Shandong Lukang Cisen Pharmaceutical, 2010-2012
LVP Output of China Otsuka Pharmaceutical, 2010-2012
Major Injection Products of China Otsuka Pharmaceutical
Injection Output and Demand in China, 2012-2015E
Output of Top 10 Injection Producers in China, 2011-2012
LVP Revenue of Major Chinese Producers, 2008-2012
LVP Gross Margin of Major Chinese Producers, 2008-2013
Proportion of LVP Sales Volume or Value (by Product) in China, 2015E
